Advertisement
AVIR Forex News
Atea Pharma Rejects Unsolicited Proposal From Tang Capital Partners
Biopharmaceutical company Atea Pharmaceuticals, Inc. (AVIR) announced Tuesday that its Board of Directors unanimously rejected the unsolicited proposal from Tang Capital Partners, LP on behalf of Concentra Biosciences, LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of Atea's programs.
RTTNews
|
698 days ago
Atea Pharma Says FDA Grants Fast Track Designation To AT-752 For Treatment Of Dengue
Biopharmaceutical company Atea Pharmaceuticals, Inc. (AVIR) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AT-752, a novel, orally administered, direct-acting antiviral for the treatment of dengue virus infection.
RTTNews
|
944 days ago
